Table 3 Recommended dose modifications within the VICTOR trial
Standard of Care (DAGO) Arm | |
|---|---|
Observation | Recommended Modification |
Serum creatinine (mmol/L) | Daunorubicin dose |
 < 105 | 100% |
105–265 | 75% |
 > 265 | 50% |
Bilirubin > 2 × ULN and AST/ALT > 2.5 × ULN | Postpone gemtuzumab ozogamicin dose until less than these levels. Consider omitting the scheduled dose if delayed more than 2 days between sequential infusions |
Bilirubin (μmol/L) | Daunorubicin dose |
 < 20 | 100% |
20–50 | 75% |
 > 50 | 50% |
Bilirubin (μmol/L) | Cytarabine dose |
 > 34 | 50% |
Venetoclax and Low-dose Cytarabine Arm | |
During venetoclax maintenance: | |
Upon reoccurrence of grade 3 or 4 non-haematological toxicity, or grade 4 haematological toxicities, except lymphopenia | |
Dose at interruption (mg) | Restart dose (mg*) |
400 | 300 |
300 | 200 |
200 | 100 |
100 | 50** |